Meridian Launches Innovative Air-Dryable™ qPCR Mixes Enabling Direct Detection of DNA or RNA from Urine Samples

Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two innovative Air-Dryable™ qPCR Mixes that enable direct detection of DNA or RNA/DNA from urine samples. Meridian developed these unique master mixes specifically to overcome the adverse effect of inhibitors present in crude urine samples that can affect the sensitivity of a molecular assay.

Urine is an abundant biofluid used to diagnose urinary tract infections (UTIs) and sexually transmitted diseases (STDs), and manage bladder, ovarian, prostate, and kidney diseases. Urine-based biopsies are non-invasive and enable convenient at-home self-sampling, consequently increasing patient compliance and satisfaction. Urine contains substances (e.g., urea) that can inhibit PCR reactions. As such, expensive and time-consuming extraction steps are often needed. Meridian’s new Air-Dryable™ Direct DNA qPCR Urine and Air-Dryable™ Direct RNA/DNA qPCR Urine mixes remove the need for time-consuming RNA or DNA purification or complex component optimization. These mixes produce faster and more sensitive assays directly from urine. Setting up the assay can be as simple as adding primers and probes. Air-Dryable™ technology replaces the need for lyophilization with fast, simple, and inexpensive oven-drying procedures. Meridian’s mixes are ideal for manufacturing room-temperature stable, highly sensitive, and cost-effective molecular diagnostic assays.

Florent Chang-Pi-Hin, Ph.D., Vice President of Research & Development at Meridian Life Science, commented, “Urine can be a rich source of material for testing a wide variety of conditions as it is easily accessible and convenient for patients to provide in comparison to other liquid biopsy material such as blood. Interestingly, we have shown that the Air-Dryable™ Direct qPCR Urine mixes are sensitive enough to detect and distinguish co-infecting arboviruses such as Dengue, Zika, and Chikungunya in urine long after the disappearance of viremia in the blood. The Air-Dryable™ Direct qPCR Urine mixes are ideal for developing point-of-care assays with faster workflows and market-leading performance. Meridian’s Air-Dryable™ technology allows oven-drying on-site, saving manufacturing time and expense while allowing control of the entire workflow.”

Meridian is committed to supplying innovative solutions to the diagnostic industry to simplify and accelerate the development of superior diagnostic assays.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”